Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN 70 30 versus HUMULIN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMULIN 70 30 versus HUMULIN N.
HUMULIN 70/30 vs HUMULIN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin replacement therapy. Human insulin is a recombinant DNA-derived polypeptide hormone that regulates glucose metabolism. Insulin binds to the insulin receptor, activating tyrosine kinase activity, which leads to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, adipose tissue), inhibition of hepatic gluconeogenesis, and promotion of glycogen synthesis and lipogenesis.
Insulin isophane (NPH) is an intermediate-acting insulin that lowers blood glucose by promoting peripheral glucose uptake, especially in muscle and adipose tissue, and inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity and downstream signaling pathways.
Subcutaneous injection, 0.5-1.0 units/kg/day divided into two doses (before breakfast and before dinner), adjusted based on blood glucose monitoring.
0.5-1 unit/kg/day subcutaneously, divided into 2 doses (morning and evening).
None Documented
None Documented
0.5-1 hour (free insulin); 8-12 hours (prolonged due to NPH component, reflecting duration of action).
Terminal half-life: 1.5-2.5 hours (subcutaneous); longer in renal impairment.
Renal: 100% (metabolized to inactive fragments; negligible excretion of intact insulin).
Renal: 60-80% as intact insulin; hepatic and renal clearance; negligible biliary/fecal elimination.
Category C
Category C
Human Insulin
Human Insulin